Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events
开发纤维蛋白特异性核探针以减少 LVAD 不良事件
基本信息
- 批准号:9607429
- 负责人:
- 金额:$ 76.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2019-12-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Kidney FailureAdverse eventAnalytical ChemistryAnimal ModelAnimalsAnticoagulationAntiplatelet DrugsAreaAvidityBenchmarkingBindingBiological MarkersBiomedical EngineeringBlood flowBlood specimenCannulasCardiologyCessation of lifeChemicalsChemistryClinicalClinical ManagementCollaborationsComplexCytolysisDataDestinationsDetectionDevelopmentDevelopment PlansDiagnosisDoctor of PhilosophyDocumentationDrug KineticsEconomicsEffectivenessEventFibrinGamma CamerasGastrointestinal HemorrhageGoalsGuidelinesHeartHeart TransplantationHeart failureHemorrhageHospital CostsHospitalizationHospitalsHousingHumanImageImpairmentImplantIn VitroIncidenceInfectionInterventionLeadershipLifeLightMechanicsMedicalMedicineNational Heart, Lung, and Blood InstituteNeurologicNuclearOperative Surgical ProceduresOrphan DrugsOutcomePatientsPharmaceutical PreparationsPharmacologic SubstancePhasePreventionProcessProductionPumpQuality of lifeRadiology SpecialtyRecurrenceRegulatory AffairsResearchResearch ContractsRodent ModelSavingsSerumSmall Business Technology Transfer ResearchSplenic InfarctionSuggestionSupport SystemTestingTherapeuticThrombosisThrombusTitaniumToxicologyTranslational ResearchTransplantationUrineWarfarinagedanalytical methodchemical synthesisfollower of religion Jewishhospital readmissionimprovedinnovationinstrumentleft ventricular assist devicemid-career facultynanomedicinenovelnuclear imagingoutcome forecastpreventproduct developmentprofessorprogramsprophylacticprototypescale upsexstability testing
项目摘要
Despite the myriad major advances in cardiology, the prognosis for patients with severe, medically
refractive heart failure (HF) is exceedingly poor. Approximately 287,000 deaths occur annually in
patients with HF who have endured an impaired quality of life often accompanied by significant
economic and personal losses due to recurrent hospitalizations. At least 58,000 of these deaths were
directly related to severe heart failure. Because the number of available heart donors (~2,200/year) has
not increased over the last decade, there is an enormous and expanding gap between medical need for
transplant and the woefully low supply of hearts.
Today's axial and centrifugal flow left ventricular assist devices (LVAD) have reduced size and
power requirements, allowing LVADs to become a therapeutic options as a bridge-to-transplantation
(BTT) and increasingly for destination-therapy (DT). Unfortunately the life-saving benefit of LVADs is
offset by potential life-threatening complications and costly hospital readmissions for bleeding, infection,
and thrombosis. Prophylactic anticoagulation to prevent intra-pump thrombus with warfarin (in addition
to an anti-platelet drug) exacerbates inherent bleeding complications induced by the high shear high
blood flow conditions of the pumps. Multicenter efforts to reduce anticoagulation guidelines tripled the
incidence of pump thrombotic complications. LDH, a nonspecific marker of RBC lysis, is currently used
as the best surrogate indicator for pump thrombosis. But, given clinical results to date, LDH is only an
insensitive probably late biomarker of LVAD fibrin accumulation.
We have innovated and demonstrated a very high avidity nuclear probe prototype, 99mTc-F4A, in
vitro, in excised LVADs operated ex vivo, and in rodent models, which sensitively localizes thrombus
accumulation in LVADs. In Phase 1 of this Fast-track proposal the effectiveness of 99mTc-F4A will be
demonstrated in a large animal model, calves (70kg), using reimplanted human LVADs (70Kg) and a
clinical gamma camera. In Phase 2 the analytical, chemical process, and regulatory development and
documentation required to transfer the product candidate (FibroScint) to contract research
organizations for GMP toll manufacturing, stability testing, and GLP toxicology will be completed.
FibroScint is anticipated to refine and individualize LVAD clinical management to reduce
bleeding events, thromboembolic complications and pump exchanges.
尽管心脏病学取得了无数重大进展,但严重的、医学上的
屈光性心力衰竭(HF)是非常糟糕的。每年约有28.7万人死亡
生活质量受损的心力衰竭患者经常伴有明显的
因反复住院造成的经济和个人损失。这些死亡中至少有58,000人是
与严重的心力衰竭直接相关。因为可用的心脏捐赠者的数量(约2,200/年)
在过去的十年里没有增加,在医疗需求之间存在着巨大的且不断扩大的差距
移植和可悲的低心脏供应。
今天的轴向和离心流左心室辅助装置(LVAD)已经缩小了体积和
电力需求,使LVAD成为治疗选择,作为移植的桥梁
(Btt),并越来越多地用于目的地治疗(Dt)。不幸的是,LVAD的救命益处是
被潜在的危及生命的并发症和因出血、感染、
和血栓形成。预防性抗凝预防华法林内泵内血栓(此外
到抗血小板药物)加剧高切高引起的固有出血并发症
泵的血液流动状况。减少抗凝指南的多中心努力使
泵血栓并发症的发生率。乳酸脱氢酶是一种红细胞溶解的非特异性标志物,目前正在使用
作为泵血栓形成的最佳替代指标。但是,根据迄今的临床结果,LDH只是一种
不敏感,可能是LVAD纤维蛋白积聚的晚期生物标志物。
我们创新并展示了一种非常高亲和力的核探测器原型99mTC-F4A,在
在体外,在体外操作的切除的LVAD中,在啮齿动物模型中,敏感地定位血栓
在左心室反搏中的累积。在此快速通道提案的第一阶段中,99mTc-F4A的有效性将为
在一个大型动物模型小牛(70公斤)中演示了,使用重新植入的人左心室(70公斤)和
临床伽马相机。在第二阶段,分析、化学流程和法规的开发以及
将候选产品(FibroScint)转移到合同研究所需的文档
GMP收费制造、稳定性测试和GLP毒理学的组织将完成。
FibroScint预计将改进和个性化LVAD临床管理,以减少
出血事件、血栓栓塞症并发症和换泵。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James Blackledge其他文献
James Blackledge的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James Blackledge', 18)}}的其他基金
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
新型多发性骨髓瘤分子靶向成像剂的开发和商业化
- 批准号:
10885315 - 财政年份:2021
- 资助金额:
$ 76.86万 - 项目类别:
Development of Fibrin-Specific Nuclear Probe to Reduce LVAD Adverse Events
开发纤维蛋白特异性核探针以减少 LVAD 不良事件
- 批准号:
9410234 - 财政年份:2017
- 资助金额:
$ 76.86万 - 项目类别:
相似海外基金
Acute kidney failure: investigation and treatment of ki dney cell injury
急性肾衰竭:肾细胞损伤的调查和治疗
- 批准号:
nhmrc : 901011 - 财政年份:1990
- 资助金额:
$ 76.86万 - 项目类别:
NHMRC Project Grants
Acute kidney failure: new methods of investigation and treatment
急性肾衰竭:研究和治疗的新方法
- 批准号:
nhmrc : 891081 - 财政年份:1989
- 资助金额:
$ 76.86万 - 项目类别:
NHMRC Project Grants